Logo image of LO3.DE

LONZA GROUP AG-REG (LO3.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:LO3 - CH0013841017 - Common Stock

604.2 EUR
+1.8 (+0.3%)
Last: 1/15/2026, 7:00:00 PM

LO3.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap42.43B
Revenue(TTM)7.09B
Net Income(TTM)733.00M
Shares70.23M
Float68.60M
52 Week HighN/A
52 Week LowN/A
Yearly Dividend4.29
Dividend Yield0.72%
EPS(TTM)16.64
PE36.31
Fwd PE28.43
Earnings (Next)01-28
IPO2002-04-03
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
LO3.DE short term performance overview.The bars show the price performance of LO3.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 4

LO3.DE long term performance overview.The bars show the price performance of LO3.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of LO3.DE is 604.2 EUR. In the past month the price increased by 3.42%.

LONZA GROUP AG-REG / LO3 Daily stock chart

LO3.DE Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to LO3.DE.


Chartmill TA Rating
Chartmill Setup Rating

LO3.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to LO3.DE. LO3.DE has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LO3.DE Financial Highlights

Over the last trailing twelve months LO3.DE reported a non-GAAP Earnings per Share(EPS) of 16.64. The EPS increased by 16.63% compared to the year before.


Industry RankSector Rank
PM (TTM) 10.33%
ROA 3.9%
ROE 8.5%
Debt/Equity 0.49
Chartmill High Growth Momentum
EPS Q2Q%6.98%
Sales Q2Q%16.98%
EPS 1Y (TTM)16.63%
Revenue 1Y (TTM)5.93%

LO3.DE Forecast & Estimates

30 analysts have analysed LO3.DE and the average price target is 743.91 EUR. This implies a price increase of 23.12% is expected in the next year compared to the current price of 604.2.

For the next year, analysts expect an EPS growth of 11.82% and a revenue growth 14.34% for LO3.DE


Analysts
Analysts80.67
Price Target743.91 (23.12%)
EPS Next Y11.82%
Revenue Next Year14.34%

LO3.DE Ownership

Ownership
Inst Owners58.43%
Ins Owners0.05%
Short Float %N/A
Short RatioN/A

About LO3.DE

Company Profile

LO3 logo image Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 19,299 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

Company Info

LONZA GROUP AG-REG

Muenchensteinerstrasse 38

Basel BASEL-STADT CH

Employees: 19299

LO3 Company Website

LO3 Investor Relations

Phone: 41613168111

LONZA GROUP AG-REG / LO3.DE FAQ

What does LO3 do?

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 19,299 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.


What is the current price of LO3 stock?

The current stock price of LO3.DE is 604.2 EUR. The price increased by 0.3% in the last trading session.


What is the dividend status of LONZA GROUP AG-REG?

LONZA GROUP AG-REG (LO3.DE) has a dividend yield of 0.72%. The yearly dividend amount is currently 4.29.


What is the ChartMill technical and fundamental rating of LO3 stock?

LO3.DE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Is LONZA GROUP AG-REG (LO3.DE) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LO3.DE.


What is the next earnings date for LO3 stock?

LONZA GROUP AG-REG (LO3.DE) will report earnings on 2026-01-28, after the market close.